Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M18.7Revenue $M1.5Net Margin (%)-398.8Z-Score-24.8
Enterprise Value $M17.2EPS $-20.1Operating Margin %-273.1F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-400.1Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %53.0Quick Ratio1.8Cash flow > EarningsN
Price/Sales2.45-y EBITDA Growth Rate %226Current Ratio1.8Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-73.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-117.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M6.5ROI % (ttm)-22.5Gross Margin Increase y-yN

Gurus Latest Trades with NVGN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVGNRonald Muhlenkamp 2013-03-31 Sold Out -0.03%$1.84 - $9.05
($3.83)
$ 2.84-26%Sold Out0
NVGNRonald Muhlenkamp 2012-12-31 Reduce-0.01%$1.5 - $10.24
($4.96)
$ 2.84-43%Reduce -49.15%18,184
NVGNRonald Muhlenkamp 2012-06-30 Buy 0.02%$1.95 - $2.5
($2.26)
$ 2.8426%New holding, 35757 sh.35,757
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVGN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NVGN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVGN :

    Quarterly/Annual Reports about NVGN:

      News about NVGN:

      Articles On GuruFocus.com
      comment on NVGN Mar 06 2013 

      More From Other Websites
      Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference Sep 03 2014
      Novogen Announces Results of General Meeting of Shareholders Aug 13 2014
      Novogen Receives Funding Support To Commence Studies In Muscular Dystrophy Aug 12 2014
      Novogen And CanTx Appoint Contract Manufacturers To Produce Clinical Batches Of Cantrixil™ Jul 25 2014
      Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant... Jun 17 2014
      5 Reasons Why We Believe Novogen Is Poised For Success Jun 05 2014
      Novogen rises 14.7% May 27 2014
      Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer May 27 2014
      Children's Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for... May 04 2014
      Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative... May 02 2014
      Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo Mar 18 2014
      Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Mar 12 2014
      Novogen Selected to Present at Cavendish Global Health Impact Forum Mar 10 2014
      Novogen appoints David Gryska as strategic advisor Mar 04 2014
      Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical... Mar 04 2014
      Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform Feb 03 2014
      Novogen to Host Corporate Update and Webcast Jan 30 2014
      Novogen to Present at Biotech Showcase™ 2014 Jan 08 2014
      Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat... Dec 20 2013
      Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology Nov 26 2013

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK